Skip to main content

Table 3 Summary of EGFR-TKI delivered among EGFR mutation positive patients

From: Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

  EGFR mutation positive
  Low PCV High PCV
(< 2.2 ng/ml) (n= 72) (≥ 2.2 ng/ml) (n= 49)
  Gefitinib Erlotinib Gefitinib Erlotinib
  No. % No. % No. % No. %
First-line 20 28 5 7 23 47 2 4
Second-line 21 29 11 15 14 29 8 16
Third-line 9 12 6 8 3 6 4 8
Further-line 2 3 14 20 2 4 4 8
Unadministered 20 28 36 50 7 14 31 63
  1. PCV: pretreatment CYFRA 21–1 value.